



JCO7 Re PCT/PTO 22 AUG 2005
box 89

PATENT
4518-0108PUS1

#4

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: LOIBNER, Hans et al. Conf.: 3426
Appl. No.: 10/524,520 Group: 1645
Filed: February 11, 2005 Examiner: UNKNOWN
For: USE OF ANTIBODIES AGAINST TUMOR-
ASSOCIATED ANTIGEN

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE
OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

August 18, 2005

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449(s), attached hereto.

II. COPIES (check at least one box)

- a. ☒ A CD-Rom is attached which contains thereon copies of all references listed on the attached PTO-1449 Form, including U.S. patents.
- b. ☐ Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

a. ☒ **DOCUMENTS IN THE ENGLISH LANGUAGE**

The patents, publications, or other information listed on the attached PTO 1449 are in the English language and therefore, do not require a statement of relevancy.

b. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☐ **ENGLISH LANGUAGE SEARCH REPORT**

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

d. ☐ **OTHER**

The following additional information is provided for the Examiner's consideration.

FEES

IV. ☒ THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b):
(check one box)

- a. ☐ within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. *(This section is not to be used with RCE's.)*
- b. ☐ within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.
- c. ☐ concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
- d. ☒ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required.
In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

V. ☐ THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

- a. ☐ No statement; therefore, a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).
- or
- b. ☐ See the statement below. No fee is required.

VI. STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby states that

- a. ☐ each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or
- b. ☐ each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- c. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.
- d. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VII. PAYMENT OF FEES (check one box)


- ☐ A check in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p) is enclosed for the above-identified fee.
- ☐ Please charge Deposit Account No. 02-2448 in the amount required by 37 C.F.R. § 1.17(p) for the above-indicated fee. This paper is submitted in triplicate.
- ☒ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on: August 16, 2005
(Date of Deposit)

BIRCH, STEWART, KOLASCH & BIRCH, LLP


(Signature)
LRS/1mt August 16, 2005
4518-0110 (Date of Signature)

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Leonard R. Svensson, #30,330

P.O. Box 747
Falls Church, VA 22040-0747
(714) 708-8555

- Attachment(s): ☒ **PTO-1449**
- ☐ Documents
- ☐ Foreign Search Report
- ☐ Fee
- ☒ **Other: CD-Rom containing references listed on PTO-1449 Form**

Form PTO-1449				ATTY. DOCKET NO. 4518-0108PUS1		APPLICATION NO. 10/524,520	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				APPLICANT LOIBNER, Hans et al.			
				FILING DATE February 11, 2005		GROUP	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US 2001/0006618	A1	2001-07-05	Goldenberg			
	US 4,643,971		1987-02-17	Frader et al.			
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

FOREIGN PATENT DOCUMENTS									
	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO
	WO	01/23005	A1	2001-04-05	WIPO				
	WO	00/69460	A1	2000-11-23	WIPO				
	WO	01/03738	A1	2001-01-18	WIPO				
	WO	93/21940	A1	1993-11-11	WIPO				
	EP	1140168	B1	2002-06-26	EPO				

OTHER DOCUMENTS	
(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)	
	(Abstract)Swayne L.C. et al. " SPECT anti-CEA monoclonal antibody detection of occult colorectal carcinoma metastases" Journal Article, Vol. 16, No. 11, November 1991, pp.849-852
	(Abstract)Edington H.D. " Radioimmunoimaging of metastatic medullary carcinoma of the thyroid gland using an indium -111 labeled monoclonal antibody to CEA" Journal Article, Vol. 104, No. 6, December 1998, pp. 1004-1010
	(Abstract)Cote R.J. et al. " Intraoperative monoclonal antibody CC49" Journal Article, Vol. 77, No. 4, February 15, 1996, pp.613-620
	(Abstract)Lechner P. et al. " Tc-99m-labeled anti-CEA antibodies in intraoperative diagnosis of colorectal cancer" Journal Article, Vol. 34, No. 1, February 1995, pp.8-14
EXAMINER	
DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449		ATTY. DOCKET NO. 4518-0108PUS1	APPLICATION NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		APPLICANT LOIBNER, Hans et al.	
		FILING DATE February 11, 2005	GROUP
OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	J.P. Chippaux and M. Goyffon. "Venoms, Antivenoms and Immunotherapy" Journal Toxicon, Vol.36, No.6, May 7, 1997, pp. 823-846		
	G. Riethmüller. et.al. "Monoclonal Antibody Therapy for Resected Dukes' C Colorectal Cancer: Seven-Year Outcome of a Multicenter Randomized Trial" Journal of Clinical Oncology, Vol.16, No.5, May 1998, pp.1788-1794		
	Tatsuaki, Nakashio et al. " Peritoneal dissemination is inhibited by treatment with antibodies against CD44H, B1 integrin, carcinostatic agents in NUGC-4 human gastric cancer cells" International Journal of Oncology, Vol. 10, 1997, pp.355-362		
	Barchi, Joseph J. Jr. " Emerging Roles of Carbohydrates and Glycomimetics in Anticancer Drug Design" Current Pharmaceutical Design, Vol. 6, 2000, pp.485-501		
	Ben-Yedidia Tamar and Arnon Ruth. " Design of Peptide and Polypeptide vaccines" Biotechnology, Vol.8, 1997, pp.442-448		
	Casadevall, Arturo and Scharff, Matthew D. " Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases" Clinical Infectious Diseases, Vol.21, 1995, pp.150-161		
	Glennie, Martin J. and Johnson, Peter W.M. " Clinical trials of antibody therapy" Journal Immunology Today, Vol.21, no. 8, August 2000, pp.403-410		
	Gollogly, V. Castronovo. " A possible role for the alpha 1-3 galactosyl epitope and natural anti-gal antibody in ontogenesis" Neoplasma Journal, Vol.43, No.5, 1996, pp.285- 289		
	Herlyn, Dorothy and Birebent Brigitte. " Advances in cancer vaccine development" the Finnish Medical Society Duodecim, Vol.31, 1999, pp.66-78		
	Lewis, Jonathan J. and Houghton, Alan N. " Definition of tumor antigens suitable for vaccine construction" Cancer Biology, Vol.6, 1995, pp.321-327		
	Melief, Cornelis J.M. et al. " Peptide-based cancer vaccines" Current Opinion in Immunology, Vol.8, 1996, pp.651-657		
	Miyake, Masayuki. et. al. " Correlation of Expression of H/Ley/Leb Antigens with Survival in Patients with Carcinoma of the Lung" The New England Journal of Medicine, July 2, 1992, pp.14-18		
	Orntoft, F. Torben and Vestergaard, Else Marie. " Clinical aspects of altered glycosylation of glycoproteins in cancer" Electrophoresis Journal, Vol.20, 1999, pp.362-371		
	Scott, Andrew M. and Welt, Sydney. "Antibody-based immunological therapies" Journal of Current Opinion on Immunology, Vol. 9. 1997, pp.717-722		
	Weitz, Jurgen MD and Herfarath, Christian MD. " Surgical Strategies and Minimal Residual Disease Detection" Seminars in Surgical Oncology, Vol.20, 2001, pp.329-333		
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			